FUSIX Trademark

Trademark Overview


On Thursday, October 12, 2017, a trademark application was filed for FUSIX with the United States Patent and Trademark Office. The USPTO has given the FUSIX trademark a serial number of 87643104. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 17, 2019. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The FUSIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
fusix

General Information


Serial Number87643104
Word MarkFUSIX
Filing DateThursday, October 12, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 17, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 20, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 20, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, June 17, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 17, 2019ABANDONMENT - NO USE STATEMENT FILED
Wednesday, November 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 12, 2018EXTENSION 1 GRANTED
Monday, November 12, 2018EXTENSION 1 FILED
Monday, November 12, 2018TEAS EXTENSION RECEIVED
Tuesday, May 15, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 20, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 20, 2018PUBLISHED FOR OPPOSITION
Wednesday, February 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 5, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 30, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 30, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 30, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 23, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 23, 2018NON-FINAL ACTION E-MAILED
Tuesday, January 23, 2018NON-FINAL ACTION WRITTEN
Monday, January 22, 2018ASSIGNED TO EXAMINER
Friday, October 20, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 16, 2017NEW APPLICATION ENTERED IN TRAM